Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1452393 | 0.91 | PTGS2 (0.40) | PTGS2DRD2DRD4CYP11B1CYP11B2 | |
| SCHEMBL1453948 | 0.85 | PTGS2 (0.33) | PTGS2DRD2DRD4CYP11B1CYP11B2 | |
| SCHEMBL1454552 | 0.84 | — | — | |
| SCHEMBL1453317 | 0.78 | DRD2 (0.31) | DRD2DRD4 | |
| SCHEMBL1452494 | 0.78 | PTGS2 (0.41) | PTGS2DRD2DRD4CYP11B1CYP11B2 | |
| SCHEMBL1453110 | 0.77 | — | — | |
| SCHEMBL1452595 | 0.75 | PTGS2 (0.38) | PTGS2DRD2DRD4CYP11B1CYP11B2 | |
| SCHEMBL1453709 | 0.74 | PTGS2 (0.32) | PTGS2DRD2DRD4 | |
| SCHEMBL1453170 | 0.73 | PTGS2 (0.32) | PTGS2 | |
| SCHEMBL1452096 | 0.72 | TRPA1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910783-B2 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | SP1, TTL, TTLL12 | PTGS2 4664/4885DRD2 2935/4885DRD4 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.